Characteristics | Immunologic responders | Immunologic non-responders | P |
---|---|---|---|
N = 236 | N = 55 | ||
Male gender | 179 (75.8) | 48 (87.3) | 0.065 |
Age at time of index date, median (IQR), years | 37.6 (32.1 - 45.3) | 42.6 (36.1 - 51.3) | <0.001 |
Caucasians | 171 (72.5) | 47 (85.5) | 0.045 |
Route of HIV infection | 0.059 | ||
Men who have sex with men | 97 (41.1) | 29 (52.7) | |
Heterosexually infected | 98 (41.5) | 14 (25.5) | |
Injection drug user | 14 (5.9) | 7 (12.7) | |
Other | 26 (11.8) | 3 (6.1) | |
Chronic HCV infection | 20 (8.5) | 8 (14.5) | 0.169 |
Cancer within 13 years prior to index date | 27 (11.4) | 10 (18.2) | 0.177 |
One or more AIDS defining events prior to index date | 114 (48.3) | 24 (43.6) | 0.532 |
One or more AIDS defining events after index date | 3 (1.3) | 2 (3.6) | 0.240 |
Diagnosed with HIV before 1 January 1995 | 94 (49.8) | 27 (49.1) | 0.210 |
Treated with zidofovir prior to index date | 219 (92.8) | 54 (98.2) | 0.465 |
Nadir CD4 cell count, median (IQR), cells/μL | 40 (10 - 82) | 40 (15 - 57) | 0.289 |
More than one year from first CD4 cell count ≤ 200 cells/μL to start of the virologically suppressed period* | 96 (40.7) | 32 (58.2) | 0.019 |
Time from start of HAART to start of the virologically suppressed period, median (IQR), years | 0.4 (0.2 - 1.1) | 0.4 (0.3 - 1.3) | 0.518 |